Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Erdafitinib and hyperphosphatemia in advanced UrC

Scott Tagawa • 29 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Erdafitinib

Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, outlines the clinical implications of hyperphosphatemia seen in advanced urotherlial carcinoma patients treated with erdafitinib and how clinicians may be able to use this in vivo biomarker in assessing the treatment of their patients. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Scott Tagawa

1:41
PSMAddition: 177Lu-PSMA-617 plus standard of care vs SoC alone in patients with mHSPC
Scott Tagawa • 3 Jun 2023
2:57
Efficacy of sacituzumab govitecan in mUC by Trop-2 expression
Scott Tagawa • 3 Jun 2023
1:51
Future directions in the field of targeted therapies for urothelial carcinoma
Scott Tagawa • 3 Jun 2023
3:07
PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC
Scott Tagawa • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals